Merck Company Stock Cash Per Share
| MRK Stock | USD 100.06 1.13 1.12% |
Merck Company fundamentals help investors to digest information that contributes to Merck's financial success or failures. It also enables traders to predict the movement of Merck Stock. The fundamental analysis module provides a way to measure Merck's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merck stock.
Merck |
Merck Company Company Cash Per Share Analysis
Merck's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Merck Cash Per Share | 4.44 X |
Most of Merck's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merck Company is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Merck Company has a Cash Per Share of 4.44 times. This is 2.07% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash per share for all United States stocks is 11.38% higher than that of the company.
Merck Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merck's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merck could also be used in its relative valuation, which is a method of valuing Merck by comparing valuation metrics of similar companies.Merck is currently under evaluation in cash per share category among its peers.
Merck ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Merck's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Merck's managers, analysts, and investors.Environmental | Governance | Social |
Merck Fundamentals
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 276.65 B | ||||
| Shares Outstanding | 2.53 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 79.45 % | ||||
| Number Of Shares Shorted | 32.79 M | ||||
| Price To Earning | 18.05 X | ||||
| Price To Book | 5.69 X | ||||
| Price To Sales | 3.94 X | ||||
| Revenue | 60.12 B | ||||
| Gross Profit | 42.08 B | ||||
| EBITDA | 6.91 B | ||||
| Net Income | 365 M | ||||
| Cash And Equivalents | 12.69 B | ||||
| Cash Per Share | 4.44 X | ||||
| Total Debt | 36.27 B | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 1.46 X | ||||
| Book Value Per Share | 17.58 X | ||||
| Cash Flow From Operations | 13.01 B | ||||
| Short Ratio | 2.70 X | ||||
| Earnings Per Share | 4.78 X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 129.97 | ||||
| Number Of Employees | 70 K | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 248.76 B | ||||
| Total Asset | 106.67 B | ||||
| Retained Earnings | 53.9 B | ||||
| Working Capital | 6.47 B | ||||
| Current Asset | 29.76 B | ||||
| Current Liabilities | 19.2 B | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 2.99 % | ||||
| Net Asset | 106.67 B | ||||
| Last Dividend Paid | 3.04 |
About Merck Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merck Company's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merck using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merck Company based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Merck Piotroski F Score and Merck Altman Z Score analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Dividend Share 3.04 | Earnings Share 4.78 | Revenue Per Share 24.931 | Quarterly Revenue Growth 0.044 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.